MedTrace Logo

Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment

NCT05427630 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-03-16

No results posted yet for this study

Summary

This pilot crossover study will evaluate 3 different potencies of inhaled cannabis (2.5%, 5%, and 10%) and inhaled placebo cannabis for the acute treatment of migraine.

Conditions

Interventions

DRUG

THC ~2.5%

Cannabis flower containing THC \~2.5%

DRUG

THC ~5%

Cannabis flower containing THC \~5%

DRUG

THC ~10%

Cannabis flower containing THC \~5%

DRUG

Sham Cannabis

Cannabis flower from which the THC and CBD have been extracted

Sponsors & Collaborators

Principal Investigators

  • Nathaniel M Schuster, MD · Center for Pain Medicine, UC San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2027-12-01
Completion
2027-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05427630 on ClinicalTrials.gov